Annie Constantin1, Paul B S Clarke2. 1. Department of Pharmacology and Therapeutics, McGill University, McIntyre Medical Building Rm. 1320, 3655 Promenade Sir William Osler, Montreal, Quebec, H3G 1Y6, Canada. 2. Department of Pharmacology and Therapeutics, McGill University, McIntyre Medical Building Rm. 1320, 3655 Promenade Sir William Osler, Montreal, Quebec, H3G 1Y6, Canada. paul.clarke@mcgill.ca.
Abstract
RATIONALE: Reinforcement-enhancing effects of nicotine occur in human subjects and laboratory rats. However, the doses used in animal studies typically exceed smoking-associated levels of exposure, and generalized behavioral activation by nicotine can potentially confound data interpretation. METHODS: During daily 60-min sessions, male adult rats pressed an "active" lever to illuminate a brief cue light. Pressing on either the active or inactive lever retracted both levers for 60 s. Nicotine (0.025-0.2 mg/kg) was given either by continuous intravenous (IV) infusion, or spaced IV pulses (3-s or 30-s/pulse), or pre-session subcutaneous (SC) injection. RESULTS: Almost all rats responded preferentially for the cue light for several weeks. After several home-cage nicotine injections, reinforcement enhancement occurred even within the first nicotine test session. Nicotine increased active lever responding without altering inactive lever responding, with effects reliably observed at doses as low as 0.1 mg/kg SC or 0.1 mg/kg/session IV. Within the session, the 0.1 mg/kg dose maximally increased active lever responding by 2-3-fold, coinciding with serum levels of 25 ng/ml. Intravenous nicotine (tested at 0.1 mg/kg/60-min session) was equally effective whether delivered by continuous infusion or in a series of equally spaced 0.003 mg/kg pulses each of 3-s or 30-s duration. CONCLUSIONS: Low doses of nicotine can potentiate responding for a primary sensory reinforcer without producing a generalized increase in lever pressing. Reinforcer enhancement by nicotine generalized to several modes of drug delivery, appeared to track circulating levels of drug, and occurred even at serum levels within the daytime range of moderate cigarette smokers.
RATIONALE: Reinforcement-enhancing effects of nicotine occur in human subjects and laboratory rats. However, the doses used in animal studies typically exceed smoking-associated levels of exposure, and generalized behavioral activation by nicotine can potentially confound data interpretation. METHODS: During daily 60-min sessions, male adult rats pressed an "active" lever to illuminate a brief cue light. Pressing on either the active or inactive lever retracted both levers for 60 s. Nicotine (0.025-0.2 mg/kg) was given either by continuous intravenous (IV) infusion, or spaced IV pulses (3-s or 30-s/pulse), or pre-session subcutaneous (SC) injection. RESULTS: Almost all rats responded preferentially for the cue light for several weeks. After several home-cage nicotine injections, reinforcement enhancement occurred even within the first nicotine test session. Nicotine increased active lever responding without altering inactive lever responding, with effects reliably observed at doses as low as 0.1 mg/kg SC or 0.1 mg/kg/session IV. Within the session, the 0.1 mg/kg dose maximally increased active lever responding by 2-3-fold, coinciding with serum levels of 25 ng/ml. Intravenous nicotine (tested at 0.1 mg/kg/60-min session) was equally effective whether delivered by continuous infusion or in a series of equally spaced 0.003 mg/kg pulses each of 3-s or 30-s duration. CONCLUSIONS: Low doses of nicotine can potentiate responding for a primary sensory reinforcer without producing a generalized increase in lever pressing. Reinforcer enhancement by nicotine generalized to several modes of drug delivery, appeared to track circulating levels of drug, and occurred even at serum levels within the daytime range of moderate cigarette smokers.
Entities:
Keywords:
Nicotine; Pharmacokinetics; Reinforcement enhancement; Route of administration; Smoking; Tobacco
Authors: Nadia Chaudhri; Anthony R Caggiula; Eric C Donny; Sheri Booth; Maysa A Gharib; Laure A Craven; Shannon S Allen; Alan F Sved; Kenneth A Perkins Journal: Psychopharmacology (Berl) Date: 2005-01-29 Impact factor: 4.530
Authors: Lynne Dawkins; Jane H Powell; Robert West; John Powell; Alan Pickering Journal: Psychopharmacology (Berl) Date: 2006-10-18 Impact factor: 4.530
Authors: Mark G LeSage; Dan E Keyler; Don Shoeman; Donna Raphael; Gregory Collins; Paul R Pentel Journal: Pharmacol Biochem Behav Date: 2002-05 Impact factor: 3.533
Authors: Kevin P Jensen; Elise E DeVito; Gerald Valentine; Ralitza Gueorguieva; Mehmet Sofuoglu Journal: Neuropsychopharmacology Date: 2015-12-31 Impact factor: 7.853
Authors: Doran J Satanove; Simon Rahman; T M Vanessa Chan; Suelynn Ren; Paul B S Clarke Journal: Psychopharmacology (Berl) Date: 2020-11-04 Impact factor: 4.530
Authors: Christopher L Robison; Theodore Kazan; Rikki L A Miller; Nicole Cova; Sergios Charntikov Journal: Behav Brain Res Date: 2021-07-03 Impact factor: 3.352